Literature DB >> 21277232

Imaging of lung cancer in the era of molecular medicine.

Mizuki Nishino1, David M Jackman, Hiroto Hatabu, Pasi A Jänne, Bruce E Johnson, Annick D Van den Abbeele.   

Abstract

Recent discoveries characterizing the molecular basis of lung cancer brought fundamental changes in lung cancer treatment. The authors review the molecular pathogenesis of lung cancer, including genomic abnormalities, targeted therapies, and resistance mechanisms, and discuss lung cancer imaging with novel techniques. Knowledge of the molecular basis of lung cancer is essential for radiologists to properly interpret imaging and assess response to therapy. Quantitative and functional imaging helps assessing the biologic behavior of lung cancer.
Copyright © 2011 AUR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21277232      PMCID: PMC3380440          DOI: 10.1016/j.acra.2010.10.020

Source DB:  PubMed          Journal:  Acad Radiol        ISSN: 1076-6332            Impact factor:   3.173


  89 in total

1.  Quantitative assessment of pulmonary perfusion with dynamic contrast-enhanced MRI.

Authors:  H Hatabu; E Tadamura; D L Levin; Q Chen; W Li; D Kim; P V Prasad; R R Edelman
Journal:  Magn Reson Med       Date:  1999-12       Impact factor: 4.668

2.  Small pulmonary nodules: volumetrically determined growth rates based on CT evaluation.

Authors:  D F Yankelevitz; A P Reeves; W J Kostis; B Zhao; C I Henschke
Journal:  Radiology       Date:  2000-10       Impact factor: 11.105

3.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

4.  Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non-small cell lung cancer.

Authors:  Binsheng Zhao; Leonard P James; Chaya S Moskowitz; Pingzhen Guo; Michelle S Ginsberg; Robert A Lefkowitz; Yilin Qin; Gregory J Riely; Mark G Kris; Lawrence H Schwartz
Journal:  Radiology       Date:  2009-07       Impact factor: 11.105

5.  Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.

Authors:  H Young; R Baum; U Cremerius; K Herholz; O Hoekstra; A A Lammertsma; J Pruim; P Price
Journal:  Eur J Cancer       Date:  1999-12       Impact factor: 9.162

6.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

Authors:  Tony S Mok; Yi-Long Wu; Sumitra Thongprasert; Chih-Hsin Yang; Da-Tong Chu; Nagahiro Saijo; Patrapim Sunpaweravong; Baohui Han; Benjamin Margono; Yukito Ichinose; Yutaka Nishiwaki; Yuichiro Ohe; Jin-Ji Yang; Busyamas Chewaskulyong; Haiyi Jiang; Emma L Duffield; Claire L Watkins; Alison A Armour; Masahiro Fukuoka
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

7.  Personalized medicine and inhibition of EGFR signaling in lung cancer.

Authors:  Adi F Gazdar
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

Review 8.  From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.

Authors:  Richard L Wahl; Heather Jacene; Yvette Kasamon; Martin A Lodge
Journal:  J Nucl Med       Date:  2009-05       Impact factor: 10.057

9.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

10.  Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials.

Authors:  David M Jackman; Vincent A Miller; Leigh-Anne Cioffredi; Beow Y Yeap; Pasi A Jänne; Gregory J Riely; Marielle Gallegos Ruiz; Giuseppe Giaccone; Lecia V Sequist; Bruce E Johnson
Journal:  Clin Cancer Res       Date:  2009-08-11       Impact factor: 12.531

View more
  18 in total

1.  Imaging-based observational databases for clinical problem solving: the role of informatics.

Authors:  Alex A T Bui; William Hsu; Corey Arnold; Suzie El-Saden; Denise R Aberle; Ricky K Taira
Journal:  J Am Med Inform Assoc       Date:  2013-06-17       Impact factor: 4.497

2.  Beyond bone biology: Lessons from team science.

Authors:  Mone Zaidi; Daria Lizneva; Sakshi Gera; Charit Taneja; Funda Korkmaz; Anisa Gumerova; Kseniia Ievleva; Naseer Ahmad; Vitaly Ryu; Li Sun; Se-Min Kim; Maria I New; Shozeb Haider; Jameel Iqbal; Clifford Rosen; Tony Yuen
Journal:  J Orthop Res       Date:  2020-07-22       Impact factor: 3.494

3.  Repurposing of bisphosphonates for the prevention and therapy of nonsmall cell lung and breast cancer.

Authors:  Agnes Stachnik; Tony Yuen; Jameel Iqbal; Miriam Sgobba; Yogesh Gupta; Ping Lu; Graziana Colaianni; Yaoting Ji; Ling-Ling Zhu; Se-Min Kim; Jianhua Li; Peng Liu; Sudeh Izadmehr; Jaya Sangodkar; Thomas Scherer; Shiraz Mujtaba; Matthew Galsky; Jorge Gomez; Solomon Epstein; Christoph Buettner; Zhuan Bian; Alberta Zallone; Aneel K Aggarwal; Shozeb Haider; Maria I New; Li Sun; Goutham Narla; Mone Zaidi
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-01       Impact factor: 11.205

4.  Bisphosphonates inactivate human EGFRs to exert antitumor actions.

Authors:  Tony Yuen; Agnes Stachnik; Jameel Iqbal; Miriam Sgobba; Yogesh Gupta; Ping Lu; Graziana Colaianni; Yaoting Ji; Ling-Ling Zhu; Se-Min Kim; Jianhua Li; Peng Liu; Sudeh Izadmehr; Jaya Sangodkar; Jack Bailey; Yathin Latif; Shiraz Mujtaba; Solomon Epstein; Terry F Davies; Zhuan Bian; Alberta Zallone; Aneel K Aggarwal; Shozeb Haider; Maria I New; Li Sun; Goutham Narla; Mone Zaidi
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-01       Impact factor: 11.205

5.  Automated image analysis tool for tumor volume growth rate to guide precision cancer therapy: EGFR-mutant non-small-cell lung cancer as a paradigm.

Authors:  Mizuki Nishino; Satoshi Wakai; Tomoyuki Hida; Suzanne E Dahlberg; Masahiro Ozaki; Hiroto Hatabu; Hisashi Tachizaki; Bruce E Johnson
Journal:  Eur J Radiol       Date:  2018-10-23       Impact factor: 3.528

6.  Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy: developing criteria to continue therapy beyond RECIST progression.

Authors:  Mizuki Nishino; Suzanne E Dahlberg; Stephanie Cardarella; David M Jackman; Michael S Rabin; Nikhil H Ramaiya; Hiroto Hatabu; Pasi A Jänne; Bruce E Johnson
Journal:  Cancer       Date:  2013-08-06       Impact factor: 6.860

Review 7.  Imaging of Precision Therapy for Lung Cancer: Current State of the Art.

Authors:  Hyesun Park; Lynette M Sholl; Hiroto Hatabu; Mark M Awad; Mizuki Nishino
Journal:  Radiology       Date:  2019-08-06       Impact factor: 11.105

Review 8.  State of the art: Response assessment in lung cancer in the era of genomic medicine.

Authors:  Mizuki Nishino; Hiroto Hatabu; Bruce E Johnson; Theresa C McLoud
Journal:  Radiology       Date:  2014-04       Impact factor: 11.105

9.  Tumor volume decrease at 8 weeks is associated with longer survival in EGFR-mutant advanced non-small-cell lung cancer patients treated with EGFR TKI.

Authors:  Mizuki Nishino; Suzanne E Dahlberg; Stephanie Cardarella; David M Jackman; Michael S Rabin; Hiroto Hatabu; Pasi A Jänne; Bruce E Johnson
Journal:  J Thorac Oncol       Date:  2013-08       Impact factor: 15.609

10.  RECIST 1.1 in NSCLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors: comparison with RECIST 1.0.

Authors:  Mizuki Nishino; Stephanie Cardarella; David M Jackman; Nikhil H Ramaiya; Michael S Rabin; Hiroto Hatabu; Pasi A Jänne; Bruce E Johnson
Journal:  AJR Am J Roentgenol       Date:  2013-07       Impact factor: 3.959

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.